Background Enzalutamide and abiraterone acetate plus prednisone, which target the
androgen receptor axis, have expanded the treatment of advanced prostate cancer …

PURPOSE Enzalutamide and abiraterone both target androgen receptor signaling but via
different mechanisms. The mechanism of action of one drug may counteract the resistance …

Purpose Enzalutamide resistance could result from raised androgens and be overcome by
combination with abiraterone acetate. PLATO (ClinicalTrials. gov identifier: NCT01995513) …

Background Abiraterone acetate and enzalutamide both improve outcomes in patients with
metastatic castration-resistant prostate cancer (mCRPC). Optimal sequencing for these …

Background The activity of enzalutamide after prior treatment with both abiraterone acetate
(abiraterone) and docetaxel has been examined in several retrospective studies. However …

Background The degree of antitumour activity of enzalutamide following disease
progression on docetaxel and abiraterone remains controversial. Objective To examine the …

Introduction Enzalutamide is a novel antiandrogen which is approved for the treatment of
metastatic, castration-resistant prostate cancer (mCRPC) after taxane-based chemotherapy …

Objective Evaluation of the comparative effectiveness of enzalutamide and abiraterone in
patients with metastatic castration-resistant prostate cancer (mCRPC) is limited to meta …

Background Abiraterone (AA) and enzalutamide (ENZA) are increasingly being used in
chemotherapy-naive patients with metastatic castration-resistant prostate cancer owing to …

Background Androgen receptor (AR) signalling remains critically important in metastatic
castration-resistant prostate cancer (mCRPC) as confirmed by recent phase III trials …